Search Patents
  • Enhancing Immunity Using Chimeric CD40 Ligand and Coronavirus Vaccine
    Publication number: 20220090134
    Abstract: The present disclosure provides methods and compositions for enhancing immunity by administering a coronavirus vaccine and a chimeric CD40L polypeptide. The coronavirus vaccine can be comprised of inactivated coronaviral particles or an antigenic polypeptide, preferably the coronavirus spike protein. The coronavirus antigenic polypeptide can be a purified antigenic polypeptide or a nucleic acid expression construct that encodes the antigenic polypeptide. The chimeric CD40L polypeptide in compositions of the invention can be a purified chimeric CD40L polypeptide or a nucleic acid expression construction that encodes the chimeric CD40L polypeptide.
    Type: Application
    Filed: September 10, 2021
    Publication date: March 24, 2022
    Applicant: Memgen, Inc.
    Inventor: Mark J. CANTWELL
  • Coronavirus vaccine
    Patent number: 11241493
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: February 8, 2022
    Assignee: CUREVAC AG
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220127615
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject.
    Type: Application
    Filed: November 10, 2021
    Publication date: April 28, 2022
    Inventors: Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel, Christy M. Hebner, Florian A. Lempp
  • Coronavirus vaccine
    Patent number: 11964012
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: April 23, 2024
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • Application of TFF2 Protein and IFN-k Protein Combination in Treatment of a Novel Coronavirus Infection
    Publication number: 20230173028
    Abstract: A TFF2 protein and an IFN-? protein are combined to treat a novel coronavirus infection. A product comprises: (a) an IFN-? protein; (b) a TFF2 protein; and (c) an optional pharmaceutically acceptable carrier. Provided are an application of a combination of IFN-? protein and TFF2 protein in the preparation of a product for the treatment of a novel coronavirus infection and related diseases, and a method for using the product to treat a novel coronavirus infection and related diseases. The foregoing combination, application, and method have excellent therapeutic effects on novel coronavirus infections, and have application prospects and social benefits.
    Type: Application
    Filed: March 30, 2020
    Publication date: June 8, 2023
    Inventors: Jianqing XU, Xiaoyan ZHANG, Weihui FU, Songhua YUAN, Yongquan HE
  • TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS
    Publication number: 20220339140
    Abstract: The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.
    Type: Application
    Filed: May 24, 2022
    Publication date: October 27, 2022
    Inventors: ERIC HOLMES, GARY OSTRANDER, GEOFFREY STUART DOW
  • CORONAVIRUS VACCINE
    Publication number: 20230338512
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: November 29, 2022
    Publication date: October 26, 2023
    Inventors: Alexander Muik, Asaf Poran, Kena Anne Swanson, Qi Yang, Hui Cai
  • CORONAVIRUS THERAPEUTIC AGENT INCLUDING Elaeocarpus sylvestris EXTRACT AS ACTIVE INGREDIENT
    Publication number: 20220313764
    Abstract: Provided is a pharmaceutical composition for preventing, alleviating or treating coronavirus infection, containing an Elaeocarpus sylvestris leaf extract as an active ingredient, and a food composition for preventing or alleviating coronavirus infection. Since the Elaeocarpus sylvestris leaf extract exhibits excellent anti-viral activity against coronavirus which is a virus causing a respiratory disease, a digestive disease, a liver disease or a brain disease in a mammal, particularly, the corona-19 virus, it may be effectively used in medicines and food for preventing, alleviating or treating a disease caused by coronavirus infection.
    Type: Application
    Filed: January 11, 2021
    Publication date: October 6, 2022
    Applicant: GENENCELL CO., LTD.
    Inventors: Se Chan KANG, Yong Joon JEONG, Hye Lin JEON, Yang Mi HER
  • TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS
    Publication number: 20210267952
    Abstract: The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.
    Type: Application
    Filed: February 19, 2021
    Publication date: September 2, 2021
    Inventors: ERIC HOLMES, GARY OSTRANDER, GEOFFREY STUART DOW
  • Compositions and methods for treating coronavirus infection and SARS
    Publication number: 20050002901
    Abstract: The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection.
    Type: Application
    Filed: March 30, 2004
    Publication date: January 6, 2005
    Inventor: Lawrence Blatt
  • FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS STRUCTURAL PROTEINS, THEIR PRODUCTION AND USES
    Publication number: 20100150923
    Abstract: Fusion proteins of recombinant SARS coronavirus structural proteins, their production and uses are provided. An optimized SARS coronavirus S protein gene which can be highly expressed in the mammalian cell strains and SARS coronavirus S protein variants comprising deletion, modification or mutation amino acids 318-510 corresponding to SARS coronavirus S protein are also provided.
    Type: Application
    Filed: June 13, 2006
    Publication date: June 17, 2010
    Applicant: Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences
    Inventors: Chengyu Jiang, Feng Guo, Shuan Rao, Bing Guan, Yi Huan, Peng Yang
  • COMPOUNDS AND METHODS FOR TREATING DISEASES AND/OR CONDITIONS CAUSED BY CORONAVIRUS
    Publication number: 20230124467
    Abstract: Compounds and compositions, for example vardenafil, for treating diseases and/or conditions caused by, arising from, and/or associated with coronavirus in a subject, for example a subject infected with SARS-CoV-2 or other coronavirus. Combinations of agents useful for treating diseases and/or conditions caused by, arising from, and/or associated with coronavirus in a subject, for example, vardenafil and Remdesivir, are also provided.
    Type: Application
    Filed: March 3, 2021
    Publication date: April 20, 2023
    Inventors: Wai Yip Thomas LEE, Chung Sing Daniel POON
  • CORONAVIRUS VACCINE
    Publication number: 20240042011
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: March 20, 2023
    Publication date: February 8, 2024
    Inventors: Alexander Muik, Asaf Poran, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin
  • CORONAVIRUS-TARGETING UNIVERSAL DC CELL VACCINE, AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20220096623
    Abstract: The present invention provides a method for preparing a coronavirus-targeting universal DC cell vaccine, and belongs to the technical field of virus vaccine preparation. The preparation method includes the following steps: ligating a fusion gene including a HLA gene and a coronavirus antigen gene onto an expression vector to obtain a recombinant vector; then transferring the recombinant vector into antigen-presenting cells to be transfected to obtain the coronavirus-targeting universal DC cell vaccine. The universal DC cell vaccine of the present invention has a targeting property against a coronavirus, can effectively stimulate a CTL, and has a killing effect on a target cell.
    Type: Application
    Filed: August 10, 2020
    Publication date: March 31, 2022
    Inventors: Shunchang JIAO, Rong ZHANG, Zishan ZHOU
  • Coronavirus vaccine
    Patent number: 11576966
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: February 14, 2023
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • METHODS OF AMELIORATING AND/OR PREVENTING CORONAVIRUS-RELATED INFECTIONS
    Publication number: 20230060588
    Abstract: The invention provides a method of ameliorating and/or preventing a coronavirus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a sugar or a derivative thereof. The invention also provides a method of ameliorating and/or preventing a coronavirus infection in a subject, the method comprising upregulating sialylation of a glycan, downregulating N-glycosylation, and/or downregulating O-glycosylation of a virus particle of the coronavirus.
    Type: Application
    Filed: August 30, 2022
    Publication date: March 2, 2023
    Applicant: Glycure LLC
    Inventors: Xi CHEN, Jian ZHANG
  • Coronavirus vaccine
    Patent number: 11596686
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: August 9, 2022
    Date of Patent: March 7, 2023
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • METHODS OF USING PROBENECID FOR TREATMENT OF CORONAVIRUS INFECTIONS
    Publication number: 20210393564
    Abstract: Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.
    Type: Application
    Filed: September 3, 2021
    Publication date: December 23, 2021
    Inventors: Ralph A. Tripp, Jackelyn Murray, Robert Jeff Hogan
  • COMPOSITION FOR NEUTRALIZING CORONAVIRUS
    Publication number: 20230165935
    Abstract: The present disclosure relates to a novel protein that specifically binds to a coronavirus, and a composition for neutralizing a coronavirus. A novel protein provided in the present disclosure is a novel protein in which virus binding ability is maintained but toxicity is eliminated on the basis of virus binding properties of bean-derived protein lectins, and thus can be used as a material for preventing the infection of a coronavirus or alleviating infectious diseases.
    Type: Application
    Filed: May 24, 2021
    Publication date: June 1, 2023
    Inventors: Du Woon Kim, Jong Youn Cho
  • Coronavirus vaccine
    Patent number: 11878055
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
    Type: Grant
    Filed: June 26, 2023
    Date of Patent: January 23, 2024
    Assignee: BioNTech SE
    Inventors: Alexander Muik, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin, Kayvon Modjarrad
Narrow Results

Filter by US Classification